Literature DB >> 33194086

Identification of novel CEBPA double mutations capable of promoting familial AML via the suppression of myeloid differentiation.

Yunjing Zheng1,2, Hui Zhang3, Qin Lu1, Xinran Chu1, Li Gao1, Peifang Xiao1, Jian Pan1, Shaoyan Hu1.   

Abstract

CCAAT-enhancer-binding protein α (CEBPA) gene carrying two mutations (CEBPA double mutations) is known to promote familial acute myeloid leukemia (AML). However, the underlying mechanism by which CEBPA double mutations promote AML remains poorly understood. Here we report that a family with three generations suffering from familial AML carries novel double mutations of CEBPA. Seven bases of GCGCGGG were inserted into the N-terminal c.113-114 of CEBPA as germline mutations and three bases of AAG were inserted into the C-terminal c.939-940 as a somatic mutation. To test the functional impact of this double mutation, we constructed plasmid encoding the double mutants of CEBPA and transfected it into the myeloid precursor 32Dcl3 cells. Lentiviral induced overexpression of CEBPA with these double mutations inhibited myeloid differentiation of these 32Dcl3 cells, and led to approximately 4-fold fewer frequency of CD11b expression. Our results confirm that the double mutations of CEBPA at both N- and C-terminals are potentially to induce leukemogenesis of AML. AJTR
Copyright © 2020.

Entities:  

Keywords:  CEBPA mutation; familial AML; germline mutation

Year:  2020        PMID: 33194086      PMCID: PMC7653564     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  15 in total

1.  Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.

Authors:  Erdogan Taskesen; Lars Bullinger; Andrea Corbacioglu; Mathijs A Sanders; Claudia A J Erpelinck; Bas J Wouters; Sonja C van der Poel-van de Luytgaarde; Frederik Damm; Jürgen Krauter; Arnold Ganser; Richard F Schlenk; Bob Löwenberg; Ruud Delwel; Hartmut Döhner; Peter J M Valk; Konstanze Döhner
Journal:  Blood       Date:  2010-12-21       Impact factor: 22.113

2.  A C-terminal mutant of CCAAT-enhancer-binding protein α (C/EBPα-Cm) downregulates Csf1r, a potent accelerator in the progression of acute myeloid leukemia with C/EBPα-Cm.

Authors:  Katsuhiro Togami; Jiro Kitaura; Tomoyuki Uchida; Daichi Inoue; Koutarou Nishimura; Kimihito C Kawabata; Reina Nagase; Sayuri Horikawa; Kumi Izawa; Tomofusa Fukuyama; Fumio Nakahara; Toshihiko Oki; Yuka Harada; Hironori Harada; Hiroyuki Aburatani; Toshio Kitamura
Journal:  Exp Hematol       Date:  2014-12-20       Impact factor: 3.084

3.  Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models.

Authors:  Naoko Kato; Jiro Kitaura; Noriko Doki; Yukiko Komeno; Naoko Watanabe-Okochi; Katsuhiro Togami; Fumio Nakahara; Toshihiko Oki; Yutaka Enomoto; Yumi Fukuchi; Hideaki Nakajima; Yuka Harada; Hironori Harada; Toshio Kitamura
Journal:  Blood       Date:  2010-09-30       Impact factor: 22.113

4.  A family harboring a germ-line N-terminal C/EBPalpha mutation and development of acute myeloid leukemia with an additional somatic C-terminal C/EBPalpha mutation.

Authors:  Tomoko Nanri; Naokuni Uike; Toshiro Kawakita; Eisaku Iwanaga; Hiroaki Mitsuya; Norio Asou
Journal:  Genes Chromosomes Cancer       Date:  2010-03       Impact factor: 5.006

5.  Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.

Authors:  Thomas Pabst; Marianne Eyholzer; Simon Haefliger; Julian Schardt; Beatrice U Mueller
Journal:  J Clin Oncol       Date:  2008-09-02       Impact factor: 44.544

6.  Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).

Authors:  Claude Preudhomme; Christophe Sagot; Nicolas Boissel; Jean-Michel Cayuela; Isabelle Tigaud; Stéphane de Botton; Xavier Thomas; Emmanuel Raffoux; Charlotte Lamandin; Sylvie Castaigne; Pierre Fenaux; Hervé Dombret
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

7.  Identification of TSC-22 as a potential tumor suppressor that is upregulated by Flt3-D835V but not Flt3-ITD.

Authors:  Y Lu; J Kitaura; T Oki; Y Komeno; K Ozaki; M Kiyono; H Kumagai; H Nakajima; T Nosaka; H Aburatani; T Kitamura
Journal:  Leukemia       Date:  2007-08-09       Impact factor: 11.528

8.  Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis.

Authors:  Hong-Ying Li; Dong-Hong Deng; Ying Huang; Fang-Hui Ye; Lu-Lu Huang; Qiang Xiao; Bing Zhang; Bing-Bing Ye; Yong-Rong Lai; Zeng-Nan Mo; Zhen-Fang Liu
Journal:  Eur J Haematol       Date:  2015-01-22       Impact factor: 2.997

9.  Disease evolution and outcomes in familial AML with germline CEBPA mutations.

Authors:  Kiran Tawana; Jun Wang; Aline Renneville; Csaba Bödör; Robert Hills; Chey Loveday; Aleksandar Savic; Frederik W Van Delft; Jennifer Treleaven; Panayiotis Georgiades; Elizabeth Uglow; Norio Asou; Naokuni Uike; Maruša Debeljak; Janez Jazbec; Philip Ancliff; Rosemary Gale; Xavier Thomas; Valerie Mialou; Konstanze Döhner; Lars Bullinger; Beatrice Mueller; Thomas Pabst; Matthias Stelljes; Brigitte Schlegelberger; Eva Wozniak; Sameena Iqbal; Jessica Okosun; Shamzah Araf; Anne-Katrine Frank; Felicia B Lauridsen; Bo Porse; Claus Nerlov; Carolyn Owen; Inderjeet Dokal; John Gribben; Matthew Smith; Claude Preudhomme; Claude Chelala; Jamie Cavenagh; Jude Fitzgibbon
Journal:  Blood       Date:  2015-07-10       Impact factor: 22.113

10.  Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis.

Authors:  T Pabst; M Eyholzer; J Fos; B U Mueller
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.